Navigation Links
CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year

-Study shows angina at one year associated with significantly higher

incidence of depression-

PALO ALTO, Calif., June 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that the Archives of Internal Medicine published results of a major study demonstrating that one in five patients studied experienced chest pain one year after a myocardial infarction (MI), or heart attack, and that this angina was associated with significantly elevated rates of depression among cardiac patients in the registry.

PREMIER (Prospective Registry Evaluating Myocardial Infarction: Events and Recovery) was a "real-world" observational study in nearly 2,500 patients specifically designed to characterize patients' health status one year after a heart attack. Researchers found a significant (p<0.001), consistent association between one year post-MI angina and depression across a wide range of demographic, prior history and treatment variables.

Patients with angina after one year also were more likely to smoke (p<0.001) and undergo revascularization (p<0.001). In addition, the study revealed that 21 percent of the patients with angina in the study suffered daily or weekly angina attacks.

The investigators reported that in patients with angina after one year, 87.9 percent were not taking calcium channel blockers, 30.8 percent were not taking beta blockers and 48.6 percent were not taking nitrates.

"After patients survive a heart attack, a primary goal of treatment is to minimize their angina and optimize their quality of life. The PREMIER study explicitly sought to illuminate the prevalence and predictors of angina after an MI. We found one in five heart attack survivors still suffered angina, and many of them suffered it daily or weekly," said John Spertus, M.D., MPH, director of health outcomes research at Mid America Heart Institute in Kansas City, Mo., and principal investigator of the PREMIER study.

"Angina is often underappreciated by physicians and significantly impacts patients' quality of life. The PREMIER study is important in that it highlights the need for better surveillance and treatment of angina to improve patients' quality of life," he added.

American College of Cardiology/American Heart Association treatment guidelines indicate that the goals for angina patients include the complete, or nearly complete, elimination of chronic angina and an improvement in functional capacity that allows a return to normal activities.

About the PREMIER Study

The PREMIER study included 2,498 U.S. patients with acute MI, recruited from 19 hospitals from January 1, 2003, through June 28, 2004. Among this multicenter cohort of patients, angina was measured by the Seattle Angina Questionnaire one year after hospitalization for MI. Investigators evaluated the sociodemographic factors, clinical history, MI presentation, inpatient treatments and outpatient treatments associated with angina at one year.

Of 1,957 post-MI patients, 389 (19.9 percent) reported angina one year after MI. Among the outpatient variables, patients with angina at one year were more likely to continue smoking, to undergo revascularization after index hospitalization (percutaneous coronary intervention or coronary artery bypass graft) and to have significant new, persistent or transient depressive symptoms.

The study was supported, in part, by grants from the National Institutes of Health and CV Therapeutics.

About Angina

Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain. Approximately 9.1 million people in the United States have chronic angina, and 500,000 new cases are diagnosed annually, according to the American Heart Association.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
3. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
4. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
(Date:11/25/2015)... 2015 AAIPharma Services Corp./Cambridge Major Laboratories, ... least $15.8  Million to expand its laboratories and ... . The expansion will provide additional office space ... demands of the pharmaceutical and biotechnology markets. ... provide up to 40,000 square feet of expanded ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
(Date:11/25/2015)... 25, 2015 Kitov Pharma ... KTOV), a biopharmaceutical company focused on the development of ... conditions, today announced the closing of its previously announced ... ADSs ), each representing 20 ordinary shares of the ... The ADSs and warrants were issued in a fixed ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
Breaking Medicine News(10 mins):